A draft Senate COVID-19 stimulus compromise floated Tuesday (March 24) maintains multiple provisions that would expand requirements for drug makers to report product shortages, give FDA authority to require device makers report shortages and potential supply disruptions, and protect manufacturers of respiratory masks from lawsuits. The draft bill, the Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748), was being hammered out by Senate Republicans and Democrats from both chambers after days of bipartisan disagreement. Title III of the...